Dana Investment Advisors Inc. Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Dana Investment Advisors Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 9.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 100,181 shares of the biopharmaceutical company’s stock after buying an additional 8,771 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Pfizer were worth $2,803,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Founders Financial Alliance LLC raised its position in Pfizer by 3.6% during the second quarter. Founders Financial Alliance LLC now owns 28,419 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 995 shares in the last quarter. 3Chopt Investment Partners LLC grew its position in Pfizer by 97.9% during the second quarter. 3Chopt Investment Partners LLC now owns 22,767 shares of the biopharmaceutical company’s stock valued at $637,000 after acquiring an additional 11,265 shares during the last quarter. Heartland Bank & Trust Co purchased a new position in shares of Pfizer during the second quarter worth approximately $596,000. IMS Capital Management lifted its holdings in shares of Pfizer by 2.0% in the 2nd quarter. IMS Capital Management now owns 104,938 shares of the biopharmaceutical company’s stock worth $3,033,000 after acquiring an additional 2,029 shares during the last quarter. Finally, Brandes Investment Partners LP boosted its stake in shares of Pfizer by 10.2% in the 2nd quarter. Brandes Investment Partners LP now owns 5,573,282 shares of the biopharmaceutical company’s stock valued at $155,871,000 after purchasing an additional 516,714 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $28.61 on Thursday. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.11. The stock has a market capitalization of $162.10 billion, a P/E ratio of -476.67, a P/E/G ratio of 1.25 and a beta of 0.68. The company’s 50-day moving average is $29.25 and its 200 day moving average is $28.31. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.67 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company increased their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, September 16th. UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, Barclays lifted their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Nine research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.